SCHEMBL1886103

SCHEMBL1886103

CCCC(=O)N(C(=O)CCC)[C@@H](CCCCN)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.43
RNPEP Q9H4A4 1/20 0.42
CPB2 Q96IY4 5/20 0.41
SLC6A5 Q9Y345 1/20 0.38
FOLH1 Q04609 1/20 0.37
GRIK1 P39086 2/20 0.37
GRIK2 Q13002 2/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36
GNAI1 P63096 1/20 0.36
CYP2D6 P10635 1/20 0.35
NFKB1 P19838 1/20 0.35
BLM P54132 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PLG P00747 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886100 1.00 GSR (0.43) GSRRNPEPCPB2SLC6A5FOLH1
SCHEMBL32679718 0.98 GSR (0.42) GSRRNPEPCPB2SLC6A5FOLH1
SCHEMBL32679720 0.98 GSR (0.42) GSRRNPEPCPB2SLC6A5FOLH1
SCHEMBL32679719 0.98 GSR (0.42) GSRRNPEPCPB2SLC6A5FOLH1
SCHEMBL9716773 0.95 CPB2 (0.38) GSRRNPEPCPB2SLC6A5GRIK1
SCHEMBL9716770 0.95 CPB2 (0.38) GSRRNPEPCPB2SLC6A5GRIK1
SCHEMBL8931801 0.90 SLC6A5 (0.45) GSRRNPEPCPB2SLC6A5GRIK1
SCHEMBL8931799 0.90 SLC6A5 (0.45) GSRRNPEPCPB2SLC6A5GRIK1
SCHEMBL9314956 0.89 SLC6A5 (0.47) GSRCPB2SLC6A5GRIK1GRIK2
SCHEMBL1532638 0.89 SLC6A5 (0.47) GSRCPB2SLC6A5GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4859653-A Use of compositions of matter containing N-acylates of alpha aminoacids for the treatment of skin MORELLE JEAN V (FR) 1989-08-22 US claimed
EP-4746847-A2 COMPOSITION & METHODS FOR REGULATING MELANOGENESIS Sytheon Ltd. (US) 2026-05-27 EP disclosed
CN-121586570-A Compositions and methods for modulating melanogenesis 赛泽恩有限公司 2026-02-27 CN disclosed
WO-2025019573-A2 COMPOSITION & METHODS FOR REGULATING MELANOGENESIS SYTHEON LTD. (US) 2025-01-23 WO disclosed
US-12171852-B1 Composition and methods for regulating melanogenesis SYTHEON LTD (US) 2024-12-24 US disclosed
US-9078864-B2 Agonists for antimicrobial peptide systems AKTHELIA PHARMACEUTICALS (IS) 2015-07-14 US disclosed
US-20110118217-A1 Agonists for Antimicrobial Peptide Systems AKTHELIA PHARMACEUTICALS (IS) 2011-05-19 US disclosed
EP-0178911-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1992-01-22 EP disclosed
EP-0178911-A2 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1986-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118217-A1 Agonists for Antimicrobial Peptide Systems VIP, GLP1R, MAVS GSR 568/4885RNPEP 1174/4885CPB2 2511/4885
US-12171852-B1 Composition and methods for regulating melanogenesis TYR, MITF, MC1R GSR 2322/4885RNPEP 1244/4885CPB2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.